Silvia Mccoll Wealth Management LLC Takes $211,000 Position in Cencora, Inc. (NYSE:COR)

Silvia Mccoll Wealth Management LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 888 shares of the company’s stock, valued at approximately $211,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fisher Asset Management LLC acquired a new stake in shares of Cencora during the 4th quarter valued at approximately $244,000. Trust Co. of Vermont acquired a new stake in shares of Cencora during the 4th quarter valued at approximately $62,000. Wahed Invest LLC acquired a new stake in shares of Cencora during the 4th quarter valued at approximately $567,000. Vanguard Group Inc. acquired a new stake in shares of Cencora during the 4th quarter valued at approximately $4,212,508,000. Finally, Hennessy Advisors Inc. acquired a new stake in shares of Cencora during the 4th quarter valued at approximately $3,307,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Cencora

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the transaction, the insider now owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the transaction, the insider now owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Steven H. Collis sold 10,754 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $67,702,698.24. The disclosure for this sale can be found here. Insiders sold 1,956,675 shares of company stock valued at $422,352,056 over the last 90 days. 15.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on COR shares. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. SVB Leerink reaffirmed an “outperform” rating and issued a $275.00 target price on shares of Cencora in a research report on Thursday. Citigroup increased their target price on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Finally, Robert W. Baird increased their target price on Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $235.30.

Cencora Stock Performance

Shares of COR traded down $1.72 during trading hours on Monday, reaching $223.58. 1,723,139 shares of the company’s stock traded hands, compared to its average volume of 1,409,780. The firm has a market capitalization of $44.59 billion, a price-to-earnings ratio of 24.65, a P/E/G ratio of 1.57 and a beta of 0.45. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.89 and a quick ratio of 0.53. Cencora, Inc. has a twelve month low of $171.65 and a twelve month high of $246.75. The business’s fifty day simple moving average is $229.12 and its two-hundred day simple moving average is $228.16.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating the consensus estimate of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The business had revenue of $68.41 billion during the quarter, compared to analysts’ expectations of $70.60 billion. During the same quarter last year, the business posted $3.50 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Analysts predict that Cencora, Inc. will post 13.44 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were paid a dividend of $0.51 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 annualized dividend and a yield of 0.91%. Cencora’s dividend payout ratio is currently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.